Literature DB >> 402206

Carcinoma of the testis.

J G Maier, B Mittemeyer.   

Abstract

Patients with Stage I or II malignant testis germ cell tumors underwent a randomized prospective study at Walter Reed Hospital, Washington, D.C., from 1968 to 1973. Pure cell lines of seminoma or choriocarcinoma were excluded. Forty patients had inguinal orchiectomy followed by irradiation to the inguinal, iliac, lumbar para-aortic, mediastinal and supraclavicular lymph nodes. Thirty-four patients (85%) in this group are alive and free of tumor a minimum of 3 years. Fifty-one patients received pre- and postoperative irradiation to primary lymphatic pathways in association with bilateral retroperitoneal lymphadenectomy as well as elective irradiation to the mediastinum and supraclavicular regions. Forty-six patients (90%) in this second group are alive and free of tumor a minimum of three years. Both treatment methods represent marked improvement in cure rates compared to lymphadenectomy and postoperative irradiation utilized prior to 1968, but no statistically significant difference from each other.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402206     DOI: 10.1002/1097-0142(197702)39:2+<981::aid-cncr2820390738>3.0.co;2-q

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Chemotherapy of disseminated testicular cancer.

Authors:  L H Einhorn; S D Williams
Journal:  West J Med       Date:  1979-07

2.  [Sequential combination chemotherapy with vinblastine/bleomycin and adriamycin/cis-dichlorodiammineplatinum (II) in non-seminomatous testicular cancer. II. Long-term results of a study with 140 patients with retroperitoneal disease (stage II) (author's transl)].

Authors:  M E Scheulen; W Bierbaum; N Niederle; H U Eickenberg; H Holfeld; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1980-08-15

3.  Immunohistological determination of proliferative activity in seminomas.

Authors:  W Düe; K P Dieckmann; V Loy
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.